Population Pharmacokinetics of Conventional and Intermittent Dosing of Liposomal Amphotericin B in Adults: a First Critical Step for Rational Design of Innovative Regimens

A Global Analysis of Mucormycosis in France: The RetroZygo Study (2005-2007)

(2012) F. Lanternier et al.   CLINICAL INFECTIOUS DISEASES

Population Pharmacokinetics of Liposomal Amphotericin B and Caspofungin in Allogeneic Hematopoietic Stem Cell Recipients

(2011) Gudrun Würthwein et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacodynamics of Echinocandins against Candida glabrata: Requirement for Dosage Escalation To Achieve Maximal Antifungal Activity in Neutropenic Hosts

(2011) Susan J. Howard et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics and Pharmacodynamics of Amphotericin B Deoxycholate, Liposomal Amphotericin B, and Amphotericin B Lipid Complex in an In Vitro Model of Invasive Pulmonary Aspergillosis

(2010) J. M. Lestner et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparison of 2 Doses of Liposomal Amphotericin B and Conventional Amphotericin B Deoxycholate for Treatment of AIDS‐Associated Acute Cryptococcal Meningitis: A Randomized, Double‐Blind Clinical Trial of Efficacy and Safety

(2010) Richard J. Hamill et al.   CLINICAL INFECTIOUS DISEASES

Therapy for fungal diseases: opportunities and priorities

(2010) David W. Denning et al.   TRENDS IN MICROBIOLOGY

Pharmacokinetics and Buccal Mucosal Concentrations of a 15 Milligram per Kilogram of Body Weight Total Dose of Liposomal Amphotericin B Administered as a Single Dose (15 mg/kg), Weekly Dose (7.5 mg/kg), or Daily Dose (1 mg/kg) in Peripheral Stem Cell Transplant Patients

(2009) P. O. Gubbins et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pulmonary Epithelial Lining Fluid Concentrations after Use of Systemic Amphotericin B Lipid Formulations

(2009) S. Weiler et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America

(2009) Peter G. Pappas et al.   CLINICAL INFECTIOUS DISEASES

A safety and feasibility study comparing an intermittent high dose with a daily standard dose of liposomal amphotericin B for persistent neutropenic fever

(2009) M. Ellis et al.   JOURNAL OF MEDICAL MICROBIOLOGY

Evaluation and Comparison of Simple Multiple Model, Richer Data Multiple Model, and Sequential Interacting Multiple Model (IMM) Bayesian Analyses of Gentamicin and Vancomycin Data Collected From Patients Undergoing Cardiothoracic Surgery

(2009) Iona Macdonald et al.   THERAPEUTIC DRUG MONITORING

Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America

(2008) Thomas J. Walsh et al.   CLINICAL INFECTIOUS DISEASES

New dosing strategies for liposomal amphotericin B in high-risk patients

(2008) Michael Ellis   CLINICAL MICROBIOLOGY AND INFECTION

Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study

(2008) Catherine Cordonnier et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS